{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and docket_id = \"FDA-2009-P-0597\" sorted by posted_date descending", "rows": [["FDA-2009-P-0597-0035", "FDA", "FDA-2009-P-0597", "FDA/CDER response to WilmerHale - Petition Partial Denial", "Other", "Partial Petition Approval and Denial", "2019-01-31T05:00:00Z", 2019, 1, "2019-01-31T05:00:00Z", null, "2019-01-31T13:17:17Z", null, 0, 0, "0900006483a2b4f4"], ["FDA-2009-P-0597-0033", "FDA", "FDA-2009-P-0597", "GlaxoSmithKline - Supplement", "Other", "Supplement (SUP)", "2013-09-25T04:00:00Z", 2013, 9, "2013-09-25T04:00:00Z", null, "2013-09-25T17:27:55Z", null, 0, 0, "09000064813c5bb4"], ["FDA-2009-P-0597-0032", "FDA", "FDA-2009-P-0597", "Interim Response to GlaxoSmithKline (Ropes & Gray LLP)", "Other", "LET-Letter", "2010-06-09T04:00:00Z", 2010, 6, "2010-06-09T04:00:00Z", null, "2013-08-11T04:40:18Z", null, 0, 0, "0900006480afef88"], ["FDA-2009-P-0597-0008", "FDA", "FDA-2009-P-0597", "Tab 13/Exhibit 13 - \"National Asthma Education and Prevention Program, National Institutes of Health, The NAEPP Expert Panel Report 3, Summary Report 2007: Guidelines for the Diagnosis and Management of Asthma (2007)\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:48Z", null, 0, 0, "0900006480a6c989"], ["FDA-2009-P-0597-0009", "FDA", "FDA-2009-P-0597", "Tab 15/Exhibit 15 - \"American Lung Association, Epidemiology & Statistics Unit, Research Program Services Division, Trends in Asthma Morbidity and Mortality (April 2009)\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:49Z", null, 0, 0, "0900006480a6c98d"], ["FDA-2009-P-0597-0016", "FDA", "FDA-2009-P-0597", "Tab 29/Exhibit 29 - \"Approved Labeling, Prescribing Information, Advair HFA\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:59Z", null, 0, 0, "0900006480a6caf3"], ["FDA-2009-P-0597-0024", "FDA", "FDA-2009-P-0597", "Tab 57/Exhibit 57 - \"PQRI Profile Comparisons Working Group, Minutes of Teleconference on February 16, 2005 \" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:10Z", null, 0, 0, "0900006480a6cd2b"], ["FDA-2009-P-0597-0026", "FDA", "FDA-2009-P-0597", "Tab 77/Exhibit 77 - \"FDA/CDER Response to Hill Dermaceuticals, Inc., March 25, 2009, re Docket NID FDA-2004-P-0215\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "BKG-Background Material", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:13Z", null, 0, 0, "0900006480a6cdd0"], ["FDA-2009-P-0597-0029", "FDA", "FDA-2009-P-0597", "Tab 81/Exhibit 81 - \"What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects, IPAC-RS Conference, November 6-8, 2006\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:19Z", null, 0, 0, "0900006480a6ce7f"], ["FDA-2009-P-0597-0004", "FDA", "FDA-2009-P-0597", "Tab 7/Exhibit 7 - \"Infectious Diseases Society of America to FDA/CDER, November 14, 2007\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:43Z", null, 0, 0, "0900006480a6c948"], ["FDA-2009-P-0597-0022", "FDA", "FDA-2009-P-0597", "Tab 54/Exhibit 54 - \"Thomas, et al., Inhaled Corticosteroids for Asthma: Impact of Practice Level Device Switching on Asthma Controls\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:07Z", null, 0, 0, "0900006480a6ccd6"], ["FDA-2009-P-0597-0011", "FDA", "FDA-2009-P-0597", "Addendum - \"Volume II of III - Table of Exhibits 21-50\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:52Z", null, 0, 0, "0900006480a6c9a2"], ["FDA-2009-P-0597-0027", "FDA", "FDA-2009-P-0597", "Tab 78/Exhibit 78 - \"FDA Response to McGuire Woods LLP, GlaxoSmithKline, Frommer Lawrence & Haug, LLP February 22, 2006\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:15Z", null, 0, 0, "0900006480a6cdd1"], ["FDA-2009-P-0597-0014", "FDA", "FDA-2009-P-0597", "Tab 27/Exhibit 27 - \"Approved Labeling, Prescribing Information, Flovent HFA\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:56Z", null, 0, 0, "0900006480a6caf0"], ["FDA-2009-P-0597-0017", "FDA", "FDA-2009-P-0597", "Tab 30/Exhibit 30 - \"FDA/CDER Response to Alza Corporation, January 28, 2005, re Docket IDs 2004P-0506/CP1, 2004P-0472/CP1,2004P-0540/CP1, and 2004P-340/CP1\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:00Z", null, 0, 0, "0900006480a6caf4"], ["FDA-2009-P-0597-0019", "FDA", "FDA-2009-P-0597", "Tab 32/Exhibit 32 - \"FDA/CDER Response to Wyeth-Ayerst Research, March 1, 1999, re Docket No. 97P-0386/CP1\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "BKG-Background Material", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:03Z", null, 0, 0, "0900006480a6cb3c"], ["FDA-2009-P-0597-0030", "FDA", "FDA-2009-P-0597", "Tab 84/Exhibit 84 - \"Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee, December 10-11, 2008, Transcript\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:20Z", null, 0, 0, "0900006480a6cf5e"], ["FDA-2009-P-0597-0031", "FDA", "FDA-2009-P-0597", "Acknowledgement Letter to GlaxoSmithKline", "Other", "ACK-Acknowledgement Letter", "2009-12-29T05:00:00Z", 2009, 12, "2009-12-29T05:00:00Z", null, "2013-08-11T03:05:59Z", null, 0, 0, "0900006480a6dd07"], ["FDA-2009-P-0597-0003", "FDA", "FDA-2009-P-0597", "Tab 1/Exhibit 1 - \"FDA/CDER Response to King Pharmaceuticals, July 29, 2009, re Docket IDs FDA-2007-P-0128 and FDA-2009-P-0040\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:41Z", null, 0, 0, "0900006480a6c930"], ["FDA-2009-P-0597-0005", "FDA", "FDA-2009-P-0597", "Tab 10/Exhibit 10 - \"PQRI Meeting Objective and Agenda (February 2005) \" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:44Z", null, 0, 0, "0900006480a6c985"], ["FDA-2009-P-0597-0007", "FDA", "FDA-2009-P-0597", "Tab 12/Exhibit 12 - \"National Vital Statistics, Deaths: Final Data for 2006, Volume 57 Report 14 (2009)\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:47Z", null, 0, 0, "0900006480a6c988"], ["FDA-2009-P-0597-0010", "FDA", "FDA-2009-P-0597", "Tab 17/Exhibit 17 - \"National Institutes of Health, National Heart, Lung, and Blood Institute, Morbidity and Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases (2007)\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:51Z", null, 0, 0, "0900006480a6c99b"], ["FDA-2009-P-0597-0021", "FDA", "FDA-2009-P-0597", "Tab 52/Exhibit 52 - \"Approved Labeling, Prescribing and Patient Information, Relenza Diskhaler\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:06Z", null, 0, 0, "0900006480a6ccd3"], ["FDA-2009-P-0597-0028", "FDA", "FDA-2009-P-0597", "Tab 80/Exhibit 80 - \"Clinical Relevance on in Vitro Particle Sizing Data, IPAC-RS Conference, November 6-8, 2006\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:17Z", null, 0, 0, "0900006480a6ce7a"], ["FDA-2009-P-0597-0006", "FDA", "FDA-2009-P-0597", "Tab 11/Exhibit 11 - \"American Lung Association, Epidemiology & Statistics Unit, Research Program Services Division, Trends in Asthma Morbidity and Mortality (2009)\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:45Z", null, 0, 0, "0900006480a6c986"], ["FDA-2009-P-0597-0020", "FDA", "FDA-2009-P-0597", "Addendum - \"Volume III of III - Table of Exhibits 51-94\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:04Z", null, 0, 0, "0900006480a6ccd0"], ["FDA-2009-P-0597-0025", "FDA", "FDA-2009-P-0597", "Tab 61/Exhibit 61 - \"The June 1999 Draft BA/BE Guidance for Nasal Aerosols and Nasal Sprays: History, Recommendations and Local Delivery Issues, Presented at OINDP Subcommittee of Advisory Committee for Pharmaceutical Science, July 2001 \" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:11Z", null, 0, 0, "0900006480a6cd2f"], ["FDA-2009-P-0597-0001", "FDA", "FDA-2009-P-0597", "GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition", "Other", "CP-Citizen Petition", "2009-12-29T05:00:00Z", 2009, 12, "2009-12-29T05:00:00Z", null, "2019-01-30T20:17:16Z", null, 0, 0, "0900006480a6c85b"], ["FDA-2009-P-0597-0002", "FDA", "FDA-2009-P-0597", "Addendum - \"Volume I of III - Table of Exhibits 1-20\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:40Z", null, 0, 0, "0900006480a6c92f"], ["FDA-2009-P-0597-0013", "FDA", "FDA-2009-P-0597", "Tab 26/Exhibit 26 - \"Approved Labeling, Prescribing Information, Flovent Diskus\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:55Z", null, 0, 0, "0900006480a6caee"], ["FDA-2009-P-0597-0015", "FDA", "FDA-2009-P-0597", "Tab 28/Exhibit 28 - \"Approved Labeling, Prescribing Information, Advair Diskus\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "BKG-Background Material", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:57Z", null, 0, 0, "0900006480a6caf1"], ["FDA-2009-P-0597-0018", "FDA", "FDA-2009-P-0597", "Tab 31/Exhibit 31 - \"FDA/CDER Response to Warner Chilcott, May 1, 2009, re Docket ID FDA-2008-P-0586\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:01Z", null, 0, 0, "0900006480a6cb3a"], ["FDA-2009-P-0597-0023", "FDA", "FDA-2009-P-0597", "Tab 56/Exhibit 56 - \"FDA/CDER Response to Ropes & Gray (AstraZeneca,LP), November, 18, 2008, re Docket ID FDA-2006-P-0073\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:43:08Z", null, 0, 0, "0900006480a6cd2a"], ["FDA-2009-P-0597-0012", "FDA", "FDA-2009-P-0597", "Tab 25/Exhibit 25 - \"Approved Labeling, Prescribing Information, Servent Diskus\" - [GlaxoSmithKline (Ropes & Gray LLP) - Citizen Petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2009-12-29T05:00:00Z", 2009, 12, null, null, "2009-12-30T00:42:53Z", null, 0, 0, "0900006480a6caed"]], "truncated": false, "filtered_table_rows_count": 34, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-2009-P-0597"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597", "results": [{"value": "FDA", "label": "FDA", "count": 34, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-P-0597", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 29, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 5, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597", "results": [{"value": 2009, "label": 2009, "count": 31, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&posted_year=2009", "selected": false}, {"value": 2010, "label": 2010, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&posted_year=2010", "selected": false}, {"value": 2013, "label": 2013, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&posted_year=2013", "selected": false}, {"value": 2019, "label": 2019, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&posted_year=2019", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2009-P-0597&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 86.48524794261903, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}